

## MAUNA KEA TECHNOLOGIES APPOINTS GILLES BRISSON CHAIRMAN OF THE BOARD

**PARIS, April 10, 2012** – Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader on the endomicroscopy market, today announced that the company's Board of Directors appointed new board member Gilles Brisson to the role of Chairman of the Board.

Mr. Gilles Brisson has served in various roles during his 20-year tenure at Rhone-Poulenc Rorer, including Senior Vice-President of Corporate Development. He led Aventis' French pharma business from 1999 to 2003 as President and CEO. Then he became Senior Vice President of Europe for Aventis and Sanofi-aventis. Mr. Gilles Brisson has been Chairman of the Supervisory Board of Innate Pharma since 2007 and since 2009 of Ethypharm.

Mr. Gilles Brisson replaces Mr. Albert Waxman in the Chairman role and is filling the Director seat previously held by Mr. Nicolas Mulliez who is stepping down from the Board for personal reasons. Mr. Waxman remains a Director.

Mr. Gilles Brisson's appointment as a Director is subject to shareholder approval at the next Shareholders' Meeting scheduled for June 15, 2012.

### **About Mauna Kea Technologies**

Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastrointestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information on Mauna Kea Technologies, visit [www.maunakeatech.com](http://www.maunakeatech.com)

### **United States**

#### **Lazar Partners Ltd.**

Erich Sandoval

Tel: +1 917 497 2867

[esandoval@lazarpartners.com](mailto:esandoval@lazarpartners.com)

### **France and Europe**

#### **ALIZE RP**

Caroline Carmagnol / Anne –Sophie Cosquéric

Tel : + 33 1 42 68 86 43 / + 33 1 42 68 86 41

[caroline@alizerp.com](mailto:caroline@alizerp.com) / [anne-sophie@alizerp.com](mailto:anne-sophie@alizerp.com)

### **Mauna Kea Technologies**

Alexander Bryson

Marketing Communications and Brand Manager

Tel: +33 (0) 1 70 08 09 92

[alexander@maunakeatech.com](mailto:alexander@maunakeatech.com)

### **NewCap.**

Investor Relations and Financial Communication

Pierre Laurent / Florent Alba

Tel : +33 1 44 71 94 94

[maunakea@newcap.fr](mailto:maunakea@newcap.fr)

**MKEA**  
**LISTED**  
NYSE  
EURONEXT